Coadministration of a cabozantinib capsule formulation with a strong CYP3A4 inhibitor increased the exposure of cabozantinib, which may increase the risk of exposure-related adverse reactions. Avoid coadministration of Cabozantinib with strong CYP3A4 inhibitors. Reduce the dosage of Cabozantinib if coadministration with strong CYP3A4 inhibitors cannot be avoided. Avoid grapefruit or grapefruit juice which may also increase exposure of cabozantinib.
Coadministration of a cabozantinib capsule formulation with a strong CYP3A4 inducer decreased the exposure of cabozantinib, which may reduce efficacy. Avoid coadministration of Cabozantinib with strong CYP3A4 inducers. Increase the dosage of Cabozantinib if coadministration with strong CYP3A4 inducers cannot be avoided. Avoid St. John’s wort which may also decrease exposure of cabozantinib.
from FDA,2023.09
Cabozantinib is a multi-kinase inhibitor that is often used in combination with ···【more】
Release date:2025-02-26Recommended:81
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that has been widely ···【more】
Release date:2025-02-25Recommended:90